跳至主要内容
临床试验/EUCTR2011-004879-36-Outside-EU/EEA
EUCTR2011-004879-36-Outside-EU/EEA进行中(未招募)不适用

Comparative study of the immunogenicity and protective efficacy of GlaxoSmithKline Biologicals’ rec-DNA Hepatitis B vaccine (10µg) with or without Hepatitis B immunoglobulin (HBIG) in newborns of Hepatitis B envelope antigen positive (HBeAg+) mothers - HBV-302 EXT:HBV-143 Y15-Y20

GlaxoSmithKline Biologicals0 个研究点目标入组 69 人开始时间: 2015年5月22日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
69

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Subjects who participated in the primary study and were interested in participating in a follow-up study.
  • Written informed consent was obtained from the subjects or subject’s parents/LAR at each of the annual time-points.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 30
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 39
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Not applicable

研究者

相似试验